Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
Mais filtros

País/Região como assunto
Intervalo de ano de publicação
1.
Nanomedicine ; 12(7): 1885-1897, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27133189

RESUMO

Conventional photodynamic therapy has shown to be beneficial in the treatment of a variety of tumors. However, one of its major limitations is the inadequate penetration depth of visible light. In order to overcome this constraint, we developed 80nm poly-methylmethacrylate core-shell fluorescent nanoparticles (FNP) loaded with the photosensitizer tetrasulfonated aluminum phthalocyanine (Ptl). To demonstrate the efficacy of our Ptl@FNP we performed in vitro and in vivo studies using a human prostate tumor model. Our data reveal that Ptl@FNP are internalized by tumor cells, favour Ptl intracellular accumulation, and efficiently trigger cell death through the generation of ROS upon irradiation with 680nm light. When directly injected into tumors intramuscularly induced in SCID mice, Ptl@FNP upon irradiation significantly reduce tumor growth with higher efficiency than the bare Ptl. Collectively, these results demonstrate that the newly developed nanoparticles may be utilized as a delivery system for antitumor phototherapy in solid cancers.


Assuntos
Indóis/administração & dosagem , Nanopartículas , Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes/administração & dosagem , Neoplasias da Próstata/tratamento farmacológico , Animais , Linhagem Celular Tumoral , Humanos , Isoindóis , Masculino , Camundongos , Camundongos SCID
2.
Mol Ther ; 21(9): 1758-66, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23760448

RESUMO

Multipotent human adipose tissue mesenchymal stromal cells (hAMSCs) are promising therapy vehicles with tumor-homing capacity that can be easily modified to deliver cytotoxicity activating systems in the proximity of tumors. In a previous work, we observed that hAMSCs are very effective delivering cytotoxicity to glioma tumors. However, these results were difficult to reconcile with the relatively few hAMSCs surviving implantation. We use a bioluminescence imaging (BLI) platform to analyze the behavior of bioluminescent hAMSCs expressing HSV-tTK in a U87 glioma model and gain insight into the therapeutic mechanisms. Tumor-implanted hAMSCs express the endothelial marker PECAM1(CD31), integrate in tumor vessels and associate with CD133-expressing glioma stem cells (GSC). Inhibition of endothelial lineage differentiation in hAMSCs by Notch1 shRNA had no effect on their tumor homing and growth-promoting capacity but abolished the association of hAMSCs with tumor vessels and CD133+ tumor cells and significantly reduced their tumor-killing capacity. The current strategy allowed the study of tumor/stroma interactions, showed that tumor promotion and tumor-killing capacities of hAMSCs are based on different mechanisms. Our data strongly suggest that the therapeutic effectiveness of hAMSCs results from their association with special tumor vascular structures that also contain GSCs.


Assuntos
Tecido Adiposo/citologia , Diferenciação Celular , Endotélio Vascular/citologia , Glioma/patologia , Células-Tronco Mesenquimais/citologia , Efeito Espectador , Linhagem Celular Tumoral , Linhagem da Célula , Terapia Baseada em Transplante de Células e Tecidos , Células Cultivadas , Glioma/irrigação sanguínea , Glioma/terapia , Humanos , Transplante de Células-Tronco Mesenquimais , Células-Tronco Mesenquimais/fisiologia , Células-Tronco Neoplásicas/fisiologia , RNA Interferente Pequeno/genética , Receptor Notch1/genética , Receptor Notch1/metabolismo
3.
Int J Mol Sci ; 15(12): 23359-76, 2014 Dec 16.
Artigo em Inglês | MEDLINE | ID: mdl-25522168

RESUMO

The objective of this study is to investigate the efficacy of hybrid constructs in comparison to bone grafts (autograft and allograft) for posterolateral lumbar fusion (PLF) in sheep, instrumented with transpedicular screws and bars. Hybrid constructs using cultured bone marrow (BM) mesenchymal stem cells (MSCs) have shown promising results in several bone healing models. In particular, hybrid constructs made by calcium phosphate-enriched cells have had similar fusion rates to bone autografts in posterolateral lumbar fusion in sheep. In our study, four experimental spinal fusions in two animal groups were compared in sheep: autograft and allograft (reference group), hydroxyapatite scaffold, and hydroxyapatite scaffold seeded with cultured and osteoinduced bone marrow MSCs (hybrid construct). During the last three days of culture, dexamethasone (dex) and beta-glycerophosphate (ß-GP) were added to potentiate osteoinduction. The two experimental situations of each group were tested in the same spinal segment (L4-L5). Spinal fusion and bone formation were studied by clinical observation, X-ray, computed tomography (CT), histology, and histomorphometry. Lumbar fusion rates assessed by CT scan and histology were higher for autograft and allograft (70%) than for mineral scaffold alone (22%) and hybrid constructs (35%). The quantity of new bone formation was also higher for the reference group, quite similar in both (autograft and allograft). Although the hybrid scaffold group had a better fusion rate than the non-hybrid scaffold group, the histological analysis revealed no significant differences between them in terms of quantity of bone formation. The histology results suggested that mineral scaffolds were partly resorbed in an early phase, and included in callus tissues. Far from the callus area the hydroxyapatite alone did not generate bone around it, but the hybrid scaffold did. In nude mice, labeled cells were induced to differentiate in vivo and monitored by bioluminescence imaging (BLI). Although the cultured MSCs had osteogenic potential, their contribution to spinal fusion when seeded in mineral scaffolds, in the conditions disclosed here, remains uncertain probably due to callus interference with the scaffolds. At present, bone autografts are better than hybrid constructs for posterolateral lumbar fusion, but we should continue to seek better conditions for efficient tissue engineering.


Assuntos
Células da Medula Óssea/citologia , Fusão Vertebral/métodos , Alicerces Teciduais , Animais , Diferenciação Celular , Feminino , Medições Luminescentes , Camundongos , Camundongos Nus , Minerais/química , Imagem Molecular , Osteogênese , Ovinos , Alicerces Teciduais/química , Tomografia Computadorizada por Raios X
4.
J Lipid Res ; 54(5): 1207-20, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23423838

RESUMO

Acid ceramidase (AC) catalyzes the hydrolysis of ceramide into sphingosine, in turn a substrate of sphingosine kinases that catalyze its conversion into the mitogenic sphingosine-1-phosphate. AC is expressed at high levels in several tumor types and has been proposed as a cancer therapeutic target. Using a model derived from PC-3 prostate cancer cells, the highly tumorigenic, metastatic, and chemoresistant clone PC-3/Mc expressed higher levels of the AC ASAH1 than the nonmetastatic clone PC-3/S. Stable knockdown of ASAH1 in PC-3/Mc cells caused an accumulation of ceramides, inhibition of clonogenic potential, increased requirement for growth factors, and inhibition of tumorigenesis and lung metastases. We developed de novo ASAH1 inhibitors, which also caused a dose-dependent accumulation of ceramides in PC-3/Mc cells and inhibited their growth and clonogenicity. Finally, immunohistochemical analysis of primary prostate cancer samples showed that higher levels of ASAH1 were associated with more advanced stages of this neoplasia. These observations confirm ASAH1 as a therapeutic target in advanced and chemoresistant forms of prostate cancer and suggest that our new potent and specific AC inhibitors could act by counteracting critical growth properties of these highly aggressive tumor cells.


Assuntos
Ceramidase Ácida/antagonistas & inibidores , Ceramidase Ácida/genética , Terapia de Alvo Molecular , Neoplasias da Próstata/genética , Ceramidase Ácida/metabolismo , Apoptose/genética , Linhagem Celular Tumoral , Ceramidas/metabolismo , Regulação Neoplásica da Expressão Gênica , Técnicas de Silenciamento de Genes , Humanos , Lisofosfolipídeos/metabolismo , Masculino , Metástase Neoplásica , Neoplasias da Próstata/patologia , Neoplasias da Próstata/terapia , Esfingosina/análogos & derivados , Esfingosina/metabolismo
5.
PLoS One ; 17(2): e0264001, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35167620

RESUMO

The role played by certain domestic species such as dogs as a translational model in comparative oncology shows great interest to develop new therapeutic strategies in brain tumors. Gliomas are a therapeutic challenge that represents the most common form of malignant primary brain tumors in humans and the second most common form in dogs. Gene-directed enzyme/prodrug therapy using adipose mesenchymal stem cells (Ad-MSCs) expressing the herpes simplex virus thymidine kinase (TK) has proven to be a promising alternative in glioblastoma therapy, through its capacity to migrate and home to the tumor and delivering local cytotoxicity avoiding other systemic administration. In this study, we demonstrate the possibility for canine Ad-MSCs (cAd-MSCs) to be genetically engineered efficiently with a lentiviral vector to express TK (TK-cAd-MSCs) and in combination with ganciclovir (GCV) prodrug demonstrated its potential antitumor efficacy in vitro and in vivo in a mice model with the human glioblastoma cell line U87. TK-cAd-MSCs maintained cell proliferation, karyotype stability, and MSCs phenotype. Genetic modification significantly affects its secretory profile, both the analyzed soluble factors and exosomes. TK-cAd-MSCs showed a high secretory profile of some active antitumor immune response cytokines and a threefold increase in the amount of secreted exosomes, with changes in their protein cargo. We also found that the prodrug protein is not released directly into the culture medium by TK-cAd-MSCs. We believe that our work provides new perspectives for glioblastoma gene therapy in dogs and a better understanding of this therapy in view of its possible implantation in humans.


Assuntos
Neoplasias Encefálicas/terapia , Ganciclovir/administração & dosagem , Glioblastoma/terapia , Herpes Simples/enzimologia , Transplante de Células-Tronco Mesenquimais/métodos , Células-Tronco Mesenquimais/citologia , Timidina Quinase/genética , Animais , Neoplasias Encefálicas/genética , Linhagem Celular Tumoral , Técnicas de Cocultura , Cães , Ganciclovir/farmacologia , Genes Transgênicos Suicidas , Terapia Genética , Glioblastoma/genética , Herpes Simples/genética , Humanos , Lentivirus/genética , Células-Tronco Mesenquimais/metabolismo , Camundongos , Timidina Quinase/metabolismo , Transdução Genética , Proteínas Virais/genética , Proteínas Virais/metabolismo , Ensaios Antitumorais Modelo de Xenoenxerto
6.
Mater Sci Eng C Mater Biol Appl ; 121: 111854, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33579487

RESUMO

Thymidine kinase expressing human adipose mesenchymal stem cells (TK-hAMSCs) in combination with ganciclovir (GCV) are an effective platform for antitumor bystander therapy in mice models. However, this strategy requires multiple TK-hAMSCs administrations and a substantial number of cells. Therefore, for clinical translation, it is necessary to find a biocompatible scaffold providing TK-hAMSCs retention in the implantation site against their rapid wash-out. We have developed a microtissue (MT) composed by TKhAMSCs and a scaffold made of polylactic acid microparticles and cell-derived extracellular matrix deposited by hAMSCs. The efficacy of these MTs as vehicles for TK-hAMSCs/GCV bystander therapy was evaluated in a rodent model of human prostate cancer. Subcutaneously implanted MTs were integrated in the surrounding tissue, allowing neovascularization and maintenance of TK-hAMSCs viability. Furthermore, MTs implanted beside tumors allowed TK-hAMSCs migration towards tumor cells and, after GCV administration, inhibited tumor growth. These results indicate that TK-hAMSCs-MTs are promising cell reservoirs for clinical use of therapeutic MSCs in bystander therapies.


Assuntos
Células-Tronco Mesenquimais , Neoplasias , Animais , Efeito Espectador , Linhagem Celular Tumoral , Ganciclovir/farmacologia , Camundongos , Neoplasias/terapia , Simplexvirus , Timidina Quinase
7.
Adv Wound Care (New Rochelle) ; 10(6): 301-316, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-32602814

RESUMO

Objective: Wound healing is a complex process that involves the interaction between different cell types and bioactive factors. Impaired wound healing is characterized by a loss in synchronization of these interactions, resulting in nonhealing chronic wounds. Chronic wounds are a socioeconomic burden, one of the most prominent clinical manifestations of diabetes, however, they lack satisfactory treatment options. The objective of this study was to develop polymeric composites that deliver ions having wound healing properties and evaluate its performance using a pressure ulcer model in diabetic mice. Approach: To develop a polymeric composite wound dressing containing ion-releasing nanoparticles for chronic wound healing. This composite was chemically and physically characterized and evaluated using a pressure ulcer wound model in diabetic (db/db) mice to explore their potential as novel wound dressing. Results: This dressing exhibits a controlled ion release and a good in vitro bioactivity. The polymeric composite dressing treatment stimulates angiogenesis, collagen synthesis, granulation tissue formation, and accelerates wound closure of ischemic wounds created in diabetic mice. In addition, the performance of the newly designed composite is remarkably better than a commercially available dressing frequently used for the treatment of low-exuding chronic wounds. Innovation: The developed nanoplatforms are cell- and growth factor free and control the host microenvironment resulting in enhanced wound healing. These nanoplatforms are available by cost-effective synthesis with a defined composition, offering an additional advantage in potential clinical application. Conclusion: Based on the obtained results, these polymeric composites offer an optimum approach for chronic wound healing without adding cells or external biological factors.


Assuntos
Diabetes Mellitus Experimental/patologia , Nanofibras/química , Neovascularização Fisiológica/efeitos dos fármacos , Polímeros/farmacologia , Cicatrização/efeitos dos fármacos , Animais , Bandagens , Sobrevivência Celular/efeitos dos fármacos , Análise Custo-Benefício , Regulação da Expressão Gênica/efeitos dos fármacos , Tecido de Granulação/patologia , Masculino , Camundongos , Camundongos Knockout , Nanofibras/ultraestrutura , Pele/patologia
8.
Int J Cancer ; 125(11): 2565-75, 2009 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-19530240

RESUMO

HER3 (ERBB3) is a catalytically inactive pseudokinase of the HER receptor tyrosine kinase family, frequently overexpressed in prostate and other cancers. Aberrant expression and mutations of 2 other members of the family, EGFR and HER2, are key carcinogenic events in several types of tumors, and both are well- validated therapeutic targets. In this study, we show that HER3 is required to maintain the motile and invasive phenotypes of prostate (DU-145) and breast (MCF-7) cancer cells in response to the HER3 ligand neuregulin-1 (NRG-1), epidermal growth factor (EGF) and fetal bovine serum. Although MCF-7 breast cancer cells appeared to require HER3 as part of an autocrine response induced by EGF and FBS, the response of DU-145 prostate cancer cells to these stimuli, while requiring HER3, did not appear to involve autocrine stimulation of the receptor. DU-145 cells required the expression of HER3 for efficient clonogenicity in vitro in standard growth medium and for tumorigenicity in immunodeficient mice. These observations suggest that prostate cancer cells derived from tumors that overexpress HER3 are dependent on its expression for the maintenance of major attributes of neoplastic aggressiveness, with or without cognate ligand stimulation.


Assuntos
Neoplasias da Mama/patologia , Proliferação de Células , Neuregulina-1/metabolismo , Neoplasias da Próstata/patologia , Receptor ErbB-3/fisiologia , Animais , Western Blotting , Neoplasias da Mama/genética , Neoplasias da Mama/metabolismo , Movimento Celular , Ensaio de Unidades Formadoras de Colônias , Progressão da Doença , Feminino , Perfilação da Expressão Gênica , Humanos , Imunoprecipitação , Masculino , Camundongos , Camundongos SCID , Invasividade Neoplásica , Neuregulina-1/genética , Análise de Sequência com Séries de Oligonucleotídeos , Neoplasias da Próstata/genética , Neoplasias da Próstata/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Células Tumorais Cultivadas , Cicatrização , Ensaios Antitumorais Modelo de Xenoenxerto
9.
Adv Healthc Mater ; 8(19): e1900849, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31478348

RESUMO

One of the main bottlenecks in the translation of nanomedicines from research to clinics is the difficulty in designing nanoparticles actively vectorized to the target tissue, a key parameter to ensure efficacy and safety. In this group, a library of poly(beta aminoester) polymers is developed, and it is demonstrated that adding specific combinations of terminal oligopeptides (OM-PBAE), in vitro transfection is cell selective. The current study aims to actively direct the nanoparticles to the liver by the addition of a targeting molecule. To achieve this objective, retinol, successfully attached to OM-PBAE, is selected as hepatic targeting moiety. It is demonstrated that organ biodistribution is tailored, achieving the desired liver accumulation. Regarding cell type transfection, antigen presenting cells in the liver are those showing the highest transfection. Thanks to proteomics studies, organ but not cellular biodistribution can be explained by the formation of differential protein coronas. Therefore, organ biodistribution is governed by differential protein corona formed when retinol is present, while cellular biodistribution is controlled by the end oligopeptides type. In summary, this work is a proof of concept that demonstrates the versatility of these OM-PBAE nanoparticles, in terms of the modification of the biodistribution of OM-PBAE nanoparticles adding active targeting moieties.


Assuntos
Portadores de Fármacos/química , Nanopartículas/química , Polímeros/química , Coroa de Proteína/química , Animais , Sobrevivência Celular , Citometria de Fluxo , Proteínas de Fluorescência Verde/química , Células HeLa , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Nanomedicina , Oligonucleotídeos Antissenso , Oligopeptídeos/química , Tamanho da Partícula , Proteômica , Células RAW 264.7 , Vitamina A/química
10.
Sci Rep ; 9(1): 9549, 2019 07 02.
Artigo em Inglês | MEDLINE | ID: mdl-31267022

RESUMO

The existence of radio- and chemotherapy-surviving cancer stem cells is currently believed to explain the inefficacy of anti-glioblastoma (GBM) therapies. The aim of this study was to determine if a therapeutic strategy specifically targeting GBM stem cells (GSC) would completely eradicate a GBM tumor. In both the in vitro and the in vivo models, ganciclovir therapy targeting proliferating GSC promotes the survival of a quiescent, stem-like cell pool capable of reproducing the tumor upon release of the therapeutic pressure. Images of small niches of therapy-surviving tumor cells show organized networks of vascular-like structures formed by tumor cells expressing CD133 or OCT4/SOX2. These results prompted the investigation of tumor cells differentiated to endothelial and pericytic lineages as a potential reservoir of tumor-initiating capacity. Isolated tumor cells with pericyte and endothelial cell lineage characteristics, grown under tumorsphere forming conditions and were able to reproduce tumors after implantation in mice.


Assuntos
Antígeno AC133/genética , Glioma/genética , Glioma/metabolismo , Células-Tronco Neoplásicas/metabolismo , Fator 3 de Transcrição de Octâmero/genética , Fatores de Transcrição SOXB1/genética , Antígeno AC133/metabolismo , Animais , Biomarcadores , Diferenciação Celular , Linhagem Celular Tumoral , Proliferação de Células , Modelos Animais de Doenças , Imunofluorescência , Regulação Neoplásica da Expressão Gênica , Genes Reporter , Glioma/tratamento farmacológico , Glioma/patologia , Humanos , Imuno-Histoquímica , Estimativa de Kaplan-Meier , Camundongos , Células-Tronco Neoplásicas/patologia , Fator 3 de Transcrição de Octâmero/metabolismo , Fatores de Transcrição SOXB1/metabolismo
11.
Biomaterials ; 29(4): 427-37, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17950456

RESUMO

A combined strategy using bioluminescence imaging, bone densitometry and histology was used to analyze the bone regeneration capacity of human bone marrow (hBMSC) and adipose tissue (hAMSC) mesenchymal stem cells, seeded in an osteoconductive arginine-glycine-aspartate (RGD) crosslinked hydrogel scaffold, implanted in a mouse calvarial bone defect. We show that firefly luciferase labeled stem cells can be monitored in vivo through a prolonged 90 days period, during which hBMSCs survive better than hAMSCs and that the density of scaffold bearing defects increased significantly more than that of defects without scaffolds.


Assuntos
Tecido Adiposo/citologia , Células da Medula Óssea/citologia , Células-Tronco Mesenquimais/citologia , Osteogênese , Crânio/citologia , Crânio/fisiologia , Animais , Movimento Celular , Proliferação de Células , Células Cultivadas , Expressão Gênica , Genes Reporter/genética , Humanos , Medições Luminescentes , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Regeneração , Crânio/anormalidades
12.
Drug Deliv ; 25(1): 472-483, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29412012

RESUMO

Glioblastoma multiforme (GBM) is the most devastating primary brain tumor due to its infiltrating and diffuse growth characteristics, a situation compounded by the lack of effective treatments. Currently, many efforts are being devoted to find novel formulations to treat this disease, specifically in the nanomedicine field. However, due to the lack of comprehensive characterization that leads to insufficient data on reproducibility, only a reduced number of nanomedicines have reached clinical phases. In this context, the aim of the present study was to use a cascade of assays that evaluate from physical-chemical and structural properties to biological characteristics, both in vitro and in vivo, and also to check the performance of nanoparticles for glioma therapy. An amphiphilic block copolymer, composed of polyester and poly(ethylene glycol; PEG) blocks, has been synthesized. Using a mixture of this copolymer and a polymer containing an active targeting moiety to the Blood Brain Barrier (BBB; Seq12 peptide), biocompatible and biodegradable polymeric nanoparticles have been prepared and extensively characterized. In vitro studies demonstrated that nanoparticles are safe for normal cells but cytotoxic for cancer cells. In vivo studies in mice demonstrated the ability of the Seq12 peptide to cross the BBB. Finally, in vivo efficacy studies using a human tumor model in SCID mice resulted in a significant 50% life-span increase, as compared with non-treated animals. Altogether, this assay cascade provided extensive pre-clinical characterization of our polymeric nanoparticles, now ready for clinical evaluation.


Assuntos
Neoplasias Encefálicas/tratamento farmacológico , Glioma/tratamento farmacológico , Nanopartículas/administração & dosagem , Polímeros/administração & dosagem , Animais , Barreira Hematoencefálica/efeitos dos fármacos , Barreira Hematoencefálica/metabolismo , Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/patologia , Bovinos , Linhagem Celular Tumoral , Avaliação Pré-Clínica de Medicamentos/métodos , Glioma/metabolismo , Glioma/patologia , Humanos , Masculino , Camundongos , Camundongos SCID , Nanopartículas/metabolismo , Polímeros/metabolismo , Ratos , Ratos Wistar , Resultado do Tratamento , Ensaios Antitumorais Modelo de Xenoenxerto/métodos
13.
Adv Healthc Mater ; 7(17): e1800335, 2018 09.
Artigo em Inglês | MEDLINE | ID: mdl-29923337

RESUMO

The encapsulation of mRNA in nanosystems as gene vaccines for immunotherapy purposes has experienced an exponential increase in recent years. Despite the many advantages envisaged within these approaches, their application in clinical treatments is still limited due to safety issues. These issues can be attributed, in part, to liver accumulation of most of the designed nanosystems and to the inability to transfect immune cells after an intravenous administration. In this context, this study takes advantage of the known versatile properties of the oligopeptide end-modified poly (ß-amino esters) (OM-PBAEs) to complex mRNA and form discrete nanoparticles. Importantly, it is demonstrated that the selection of the appropriate end-oligopeptide modifications enables the specific targeting and major transfection of antigen-presenting cells (APC) in vivo, after intravenous administration, thus enabling their use for immunotherapy strategies. Therefore, with this study, it can be confirmed that OM-PBAE are appropriate systems for the design of mRNA-based immunotherapy approaches aimed to in vivo transfect APCs and trigger immune responses to fight either tumors or infectious diseases.


Assuntos
Células Apresentadoras de Antígenos/metabolismo , RNA Mensageiro/administração & dosagem , RNA Mensageiro/metabolismo , Animais , Linhagem Celular , Sobrevivência Celular , Portadores de Fármacos/química , Células HeLa , Humanos , Imunoterapia , Camundongos , Camundongos Endogâmicos BALB C , Nanopartículas/química , Polímeros/química , Células RAW 264.7
14.
Mol Ther Oncolytics ; 11: 39-51, 2018 Dec 21.
Artigo em Inglês | MEDLINE | ID: mdl-30364660

RESUMO

A preclinical model of glioblastoma (GB) bystander cell therapy using human adipose mesenchymal stromal cells (hAMSCs) is used to address the issues of cell availability, quality, and feasibility of tumor cure. We show that a fast proliferating variety of hAMSCs expressing thymidine kinase (TK) has therapeutic capacity equivalent to that of TK-expressing hAMSCs and can be used in a multiple-inoculation procedure to reduce GB tumors to a chronically inhibited state. We also show that up to 25% of unmodified hAMSCs can be tolerated in the therapeutic procedure without reducing efficacy. Moreover, mimicking a clinical situation, tumor debulking previous to cell therapy inhibits GB tumor growth. To understand these striking results at a cellular level, we used a bioluminescence imaging strategy and showed that tumor-implanted therapeutic cells do not proliferate, are unaffected by GCV, and spontaneously decrease to a stable level. Moreover, using the CLARITY procedure for tridimensional visualization of fluorescent cells in transparent brains, we find therapeutic cells forming vascular-like structures that often associate with tumor cells. In vitro experiments show that therapeutic cells exposed to GCV produce cytotoxic extracellular vesicles and suggest that a similar mechanism may be responsible for the in vivo therapeutic effectiveness of TK-expressing hAMSCs.

15.
Biomaterials ; 28(17): 2718-28, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17346789

RESUMO

Recent developments in stem cell research have promoted a flourishing of new biomaterials and scaffolds for tissue repair. However, there is a scarcity of procedures to monitor the performance of scaffold-stem cell combinations implanted in live animals, avoiding the inherent artefacts associated with in vitro assay conditions. We report the implementation of a procedure based on the use of the luciferase gene as a cell proliferation tracer to monitor, by in vivo non-invasive imaging, the performance of stem cell-biomaterial combinations used for tissue regeneration. In a model system using immunodepressed mice we show preference of a mouse embryonic mesenchymal cell line (C3H/10T1/2) for specific implantation sites and biomaterials during a prolonged in vivo growth period (3 months). Moreover, we analyzed the safety of implanted cells using a sensitive luminometric procedure and showed that the implanted cells did not spread to other organs. Our results demonstrate the utility of this simple and resource-saving procedure in the development and screening of biomaterials for tissue engineering.


Assuntos
Materiais Biocompatíveis , Células-Tronco Embrionárias/citologia , Imageamento Tridimensional/métodos , Fótons , Animais , Movimento Celular , Proliferação de Células , Estabilidade Enzimática , Fluorescência , Hidrogel de Polietilenoglicol-Dimetacrilato/metabolismo , Luciferases/metabolismo , Luminescência , Camundongos , Camundongos Nus , Microesferas , Músculo Esquelético/citologia , Próteses e Implantes
16.
Addiction ; 102(8): 1261-8, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17624976

RESUMO

AIMS: To estimate the life-time and 12-month prevalence of illicit drug use among Mexican adolescents, the age of onset of first drug use and the socio-demographic correlates. METHOD: A multi-stage probability survey of adolescents aged 12-17 years residing in the Mexico City Metropolitan Area was carried out in 2005. Adolescents were administered the computer-assisted adolescent version of the World Mental Health Composite International Diagnostic Interview by trained lay interviewers in their homes. The response rate was 71% (n = 3005). Descriptive and logistic regression analyses were performed considering the multi-stage and weighted sample design of the survey. FINDINGS: Of the adolescents, 5.2% have ever tried illicit drugs, 2.9% in the last 12 months. The most frequently used drugs are marijuana, followed by tranquilizers/stimulants. The median age of first use is 14 years. Correlates of life-time drug use are older age, having dropped out of school, parental drug problems, low religiosity and low parental monitoring. CONCLUSIONS: While drug use among Mexican adolescents is lower than among adolescents from other developed countries, its increasing prevalence with age and the narrowing male/female ratio calls for firm public health actions, particularly prevention strategies.


Assuntos
Serviços de Saúde Mental , Relações Pais-Filho/etnologia , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Adolescente , Criança , Feminino , Inquéritos Epidemiológicos , Humanos , Masculino , Abuso de Maconha/epidemiologia , Abuso de Maconha/psicologia , México/epidemiologia , Prevalência , Transtornos Relacionados ao Uso de Substâncias/diagnóstico , Inquéritos e Questionários/normas
17.
Drug Alcohol Depend ; 90(2-3): 128-34, 2007 Oct 08.
Artigo em Inglês | MEDLINE | ID: mdl-17382489

RESUMO

The earliest stage of drug involvement is being presented with the opportunity to use drugs. During adolescence these opportunities increase. Because of the scarcity of data for the Mexican population, the aim is to estimate the prevalence of drug use opportunities among Mexican adolescents, the prevalence of drug use among those who were presented with the opportunity, and the socio-demographic correlates of both. A multistage probability survey was carried out among 12-17 year olds from Mexico City. Adolescents were administered the adolescent version of the World Mental Health Composite International Diagnostic Interview. The response rate was 71% (n=3005). Descriptive and logistic regression analyses were performed considering the multistage and weighted sample design. Twenty-nine percent has had the opportunity to try illicit drugs; of those presented with an opportunity, 18% has done so. Males, older adolescents, school drop-outs, and those whose parent has had drug problems are more likely to have been exposed to drug use opportunities while more religious adolescents are less likely. Given the chance to try drugs, older adolescents and school drop-outs are more likely to do so and those with high parental monitoring and religiosity are less likely. These results suggest that less substance use among females in Mexico may be due in part to fewer opportunities to use since females were equally likely to use drugs given the opportunity. Given the increase in opportunity among older adolescents, preventive efforts should start by age 12 and with special attention to adolescents who have dropped out of school.


Assuntos
Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Adolescente , Área Programática de Saúde , Feminino , Seguimentos , Humanos , Incidência , Masculino , México/epidemiologia , Prevalência
18.
Mol Ther Nucleic Acids ; 8: 395-403, 2017 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-28918039

RESUMO

The use of non-viral procedures, together with CRISPR/Cas9 genome-editing technology, allows the insertion of single-copy therapeutic genes at pre-determined genomic sites, overcoming safety limitations resulting from random gene insertions of viral vectors with potential for genome damage. In this study, we demonstrate that combination of non-viral gene delivery and CRISPR/Cas9-mediated knockin via homology-directed repair can replace the use of viral vectors for the generation of genetically modified therapeutic cells. We custom-modified human adipose mesenchymal stem cells (hAMSCs), using electroporation as a transfection method and CRISPR/Cas9-mediated knockin for the introduction and stable expression of a 3 kb DNA fragment including the eGFP (selectable marker) and a variant of the herpes simplex virus 1 thymidine kinase genes (therapeutic gene), under the control of the human elongation factor 1 alpha promoter in exon 5 of the endogenous thymidine kinase 2 gene. Using a U87 glioma model in SCID mice, we show that the therapeutic capacity of the new CRISPR/Cas9-engineered hAMSCs is equivalent to that of therapeutic hAMSCs generated by introduction of the same therapeutic gene by transduction with a lentiviral vector previously published by our group. This strategy should be of general use to other applications requiring genetic modification of therapeutic cells.

19.
Oncotarget ; 8(48): 83384-83406, 2017 Oct 13.
Artigo em Inglês | MEDLINE | ID: mdl-29137351

RESUMO

MicroRNAs are critical regulators of gene networks in normal and abnormal biological processes. Focusing on invasive ductal breast cancer (IDC), we have found dysregulated expression in tumor samples of several microRNAs, including the miR-200 family, along progression from primary tumors to distant metastases, further reflected in higher blood levels of miR-200b and miR-7 in IDC patients with regional or distant metastases relative to patients with primary node-negative tumors. Forced expression of miR-200s in MCF10CA1h mammary cells induced an enhanced epithelial program, aldehyde dehydrogenase (ALDH) activity, mammosphere growth and ability to form branched tubuloalveolar structures while promoting orthotopic tumor growth and lung colonization in vivo. MiR-200s also induced the constitutive activation of the PI3K-Akt signaling through downregulation of PTEN, and the enhanced mammosphere growth and ALDH activity induced in MCF10CA1h cells by miR-200s required the activation of this signaling pathway. Interestingly, the morphology of tumors formed in vivo by cells expressing miR-200s was reminiscent of metaplastic breast cancer (MBC). Indeed, the epithelial components of MBC samples expressed significantly higher levels of miR-200s than their mesenchymal components and displayed a marker profile compatible with luminal progenitor cells. We propose that microRNAs of the miR-200 family promote traits of highly proliferative breast luminal progenitor cells, thereby exacerbating the growth and metastatic properties of transformed mammary epithelial cells.

20.
Clin Cancer Res ; 11(3): 1253-8, 2005 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-15709196

RESUMO

PURPOSE: Primary tumor growth is usually assessed by measuring tumor mass or volume, under the assumption that such variables correlate with the contents of tumor cells. However, tumors are complex interacting mixtures of tumor cells and host components. The different sensitivity of such components to cytostatic agents should be taken into consideration when evaluating the effectiveness of antineoplastic agents. We evaluate the effect of the antineoplastic agent paclitaxel on primary tumors expressing luciferase and their metastases using a sensitive luminescence-based procedure to directly asses the number tumor cells, in comparison with traditionally used tumor mass measurement. EXPERIMENTAL DESIGN: Nude mice bearing human prostate tumors expressing the luciferase gene, LNCaP.Sluc, DU 145.Sluc, and PC-3.Sluc, i.m. inoculated, and PC-3M.Sluc, orthotopically inoculated, were subjected to a 10-day treatment with either 10 mg/kg/d paclitaxel or saline solution. At the end of the treatment period, primary tumors as well as metastasis target organs were harvested, weighed, and homogenized. The presence of tumor cells in the tissue homogenates was evaluated using a luminometer, following the addition of luciferin. Tumor cell equivalent is defined as the amount of light produced by a single tumor cell in culture. RESULTS: Paclitaxel had a different effect on the primary tumor mass and the contents of tumor cells for each tumor type. Whereas LNCaP.Sluc, PC-3.Sluc, and PC-3M.Sluc primary tumor masses were significantly reduced by the action of paclitaxel, their contents in tumor cell equivalents were not significantly affected. In contrast, paclitaxel only reduced significantly the number of tumor cell equivalents in DU 145 primary tumors. In the lymph nodes, paclitaxel reduced the number of DU 145.Sluc metastases significantly, by a factor of 10(3), but had no significant effect on the rest of tumor cells. However, in lungs and muscle, paclitaxel treatment reduced significantly the number of metastatic PC-3.Sluc and PC-3M.Sluc tumor cell equivalents. In the bones, no tumor cell type was significantly affected by paclitaxel. CONCLUSIONS: Some components of tumor stroma seem to be more sensitive to antineoplastic agents than the tumor cells themselves and may also contribute to modulate the response to therapy. Our results caution against the use of a single general variable, such as tumor mass, to evaluate the effectiveness of antineoplastic agents and emphasize the effect of the tumor cell environment in their sensitivity to treatment.


Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Luciferases/metabolismo , Paclitaxel/uso terapêutico , Neoplasias da Próstata/tratamento farmacológico , Animais , Antineoplásicos Fitogênicos/administração & dosagem , Linhagem Celular Tumoral , Regulação Enzimológica da Expressão Gênica , Humanos , Luciferases/genética , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Metástase Neoplásica , Paclitaxel/administração & dosagem , Neoplasias da Próstata/genética , Neoplasias da Próstata/patologia , Transfecção , Resultado do Tratamento , Ensaios Antitumorais Modelo de Xenoenxerto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA